Where Are We with RPE Replacement Therapy? A Translational Review from the Ophthalmologist Perspective.

Stargardt disease age related macular degeneration embryonic stem cells induced pluripotent stem cells replacement retinal pigmented epithelium

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
08 Jan 2022
Historique:
received: 10 12 2021
revised: 28 12 2021
accepted: 30 12 2021
entrez: 21 1 2022
pubmed: 22 1 2022
medline: 23 2 2022
Statut: epublish

Résumé

The retinal pigmented epithelium (RPE) plays a pivotal role in retinal homeostasis. It is therefore an interesting target to fill the unmet medical need of different retinal diseases, including age-related macular degeneration and Stargardt disease. RPE replacement therapy may use different cellular sources: induced pluripotent stem cells or embryonic stem cells. Cells can be transferred as suspension on a patch with different surgical approaches. Results are promising although based on very limited samples. In this review, we summarize the current progress of RPE replacement and provide a comparative assessment of different published approaches which may become standard of care in the future.

Identifiants

pubmed: 35054869
pii: ijms23020682
doi: 10.3390/ijms23020682
pmc: PMC8775975
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Int Rev Cytol. 2000;196:245-313
pubmed: 10730217
Nat Biotechnol. 2018 Apr;36(4):328-337
pubmed: 29553577
Stem Cell Res Ther. 2020 Feb 3;11(1):47
pubmed: 32014053
Ageing Res Rev. 2015 Nov;24(Pt B):286-98
pubmed: 26369358
Nat Protoc. 2009;4(6):811-24
pubmed: 19444239
Biomaterials. 2014 Dec;35(37):9777-9788
pubmed: 25220295
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):311-320
pubmed: 29346488
Stem Cells Transl Med. 2013 May;2(5):384-93
pubmed: 23599499
Expert Opin Biol Ther. 2017 Sep;17(9):1113-1126
pubmed: 28664762
Mol Aspects Med. 2012 Aug;33(4):295-317
pubmed: 22542780
Lancet. 2005 Jun 18-24;365(9477):2071-3
pubmed: 15964431
Adv Exp Med Biol. 2018;1085:139-151
pubmed: 30578500
Lancet. 2012 Feb 25;379(9817):713-20
pubmed: 22281388
Stem Cells. 2009 Sep;27(9):2126-35
pubmed: 19521979
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:553-572
pubmed: 31914900
Prog Retin Eye Res. 2017 Sep;60:201-218
pubmed: 28336424
Stem Cell Reports. 2018 Sep 11;11(3):681-695
pubmed: 30122442
Eur J Pharmacol. 2016 Sep 15;787:84-93
pubmed: 27044435
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Cell Stem Cell. 2009 Oct 2;5(4):396-408
pubmed: 19796620
Prog Retin Eye Res. 2010 Mar;29(2):95-112
pubmed: 19961953
Am J Ophthalmol. 2007 Apr;143(4):584-95
pubmed: 17303061
Science. 1998 Nov 6;282(5391):1145-7
pubmed: 9804556
Nat Biotechnol. 2008 Jan;26(1):101-6
pubmed: 18059259
Adv Exp Med Biol. 2019;1186:99-119
pubmed: 31654387
Sci Transl Med. 2019 Jan 16;11(475):
pubmed: 30651323
Ophthalmology. 2018 Nov;125(11):1765-1775
pubmed: 29884405
J Control Release. 2015 Dec 10;219:652-668
pubmed: 26435454
Biologics. 2021 Jul 27;15:299-306
pubmed: 34349498
J Pathol. 2014 Jan;232(2):151-64
pubmed: 24105633
Cell. 2012 Oct 26;151(3):576-89
pubmed: 23101626
Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5430-7
pubmed: 14638748
J Ocul Pharmacol Ther. 2016 Jun;32(5):317-30
pubmed: 27182743
Invest Ophthalmol Vis Sci. 2015 Jan 20;56(2):1002-13
pubmed: 25604686
Curr Stem Cell Res Ther. 2020;15(2):89-97
pubmed: 31854278
Br J Ophthalmol. 2017 Jan;101(1):25-30
pubmed: 27491360
Autophagy. 2014;10(11):1989-2005
pubmed: 25484094
Br J Ophthalmol. 2002 Feb;86(2):209-13
pubmed: 11815349
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Am J Ophthalmol. 2002 Sep;134(3):411-31
pubmed: 12208254
Stem Cell Res Ther. 2021 Apr 21;12(1):248
pubmed: 33883023
Cell Prolif. 2021 Sep;54(9):e13100
pubmed: 34347352
Curr Mol Med. 2010 Dec;10(9):802-23
pubmed: 21091424
Clin Exp Ophthalmol. 2018 Aug;46(6):670-686
pubmed: 29205705
Lancet. 2015 Feb 7;385(9967):509-16
pubmed: 25458728
Nat Commun. 2020 Mar 30;11(1):1609
pubmed: 32231223
Stem Cells Dev. 2019 Sep 1;28(17):1151-1166
pubmed: 31210100
J Clin Med. 2020 Jul 13;9(7):
pubmed: 32668747
Dev Ophthalmol. 2014;53:133-42
pubmed: 24732767
Br J Ophthalmol. 2021 Jun;105(6):829-837
pubmed: 32727729
Invest Ophthalmol Vis Sci. 2016 Apr 1;57(5):ORSFc1-9
pubmed: 27116660

Auteurs

Raffaele Raimondi (R)

IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.

Piero Zollet (P)

IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.

Francesco Paolo De Rosa (FP)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.

Panagiotis Tsoutsanis (P)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.

Matteo Stravalaci (M)

IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.

Marianna Paulis (M)

IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.
Institute of Genetic and Biomedical Research (IRGB), UOS of Milan, National Research Council of Italy, 20138 Milan, Italy.

Antonio Inforzato (A)

IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano-Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.

Mario R Romano (MR)

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele-Milan, Italy.
Eye Center, Humanitas Gavazzeni-Castelli, 24128 Bergamo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH